ArticleGynecologic oncology reports2023

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.

Blair McNamara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.